Form 8-K - Current report:
SEC Accession No. 0001819790-24-000127
Filing Date
2024-11-13
Accepted
2024-11-13 16:06:23
Documents
15
Period of Report
2024-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tars-20241113.htm   iXBRL 8-K 26936
2 EX-99.1 exhibit991tarsus11132024pr.htm EX-99.1 139653
6 picture1a.jpg GRAPHIC 5866
  Complete submission text file 0001819790-24-000127.txt   318323

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tars-20241113.xsd EX-101.SCH 1773
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tars-20241113_lab.xml EX-101.LAB 22530
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tars-20241113_pre.xml EX-101.PRE 13037
17 EXTRACTED XBRL INSTANCE DOCUMENT tars-20241113_htm.xml XML 2832
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39614 | Film No.: 241454113
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)